. • Up next: Watching for range of near-term catalysts across Merck's diverse portfolio. In addition to watching the HCV triplet data (C- CREST) at AASLD and potential doublet launch later this year/early 2016. In the long term, we expect 2016-17 updates and data from assets such as second-generation